ESSA Pharma Inc. financial data

Symbol
EPIX on Nasdaq
Location
Suite 720, 999 West Broadway, Vancouver, British Columbia, Canada
Fiscal year end
September 30
Latest financial report
10-Q - Q2 2025 - Aug 13, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 4.61K % +21.3%
Debt-to-equity 2.33 % -17.7%
Return On Equity -21.7 % -7.54%
Return On Assets -21.2 % -8.05%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 47.3M shares +6.63%
Common Stock, Shares, Outstanding 44.4M shares +0.04%
Entity Public Float 377M USD +378%
Common Stock, Value, Issued 280M USD +0.04%
Weighted Average Number of Shares Outstanding, Basic 44.4M shares +0.05%
Weighted Average Number of Shares Outstanding, Diluted 44.4M shares +0.05%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 18.6M USD -19.3%
General and Administrative Expense 17M USD +46.5%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -7.23M USD +0.89%
Net Income (Loss) Attributable to Parent -25.3M USD +8.69%
Earnings Per Share, Basic 0 USD/shares +9.68%
Earnings Per Share, Diluted -0.09 USD/shares +43.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 86M USD -0.04%
Assets, Current 111M USD -16.3%
Operating Lease, Right-of-Use Asset 0 USD -100%
Assets 111M USD -16.7%
Accounts Payable, Current 971K USD -49.1%
Accrued Liabilities, Current 454K USD -47.7%
Liabilities, Current 1.6M USD -55.2%
Operating Lease, Liability, Noncurrent 154K USD -39%
Liabilities 1.6M USD -57.9%
Accumulated Other Comprehensive Income (Loss), Net of Tax -2.1M USD +0.16%
Retained Earnings (Accumulated Deficit) -227M USD -12.5%
Stockholders' Equity Attributable to Parent 109M USD -15.5%
Liabilities and Equity 111M USD -16.7%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -6.47M USD +4.67%
Net Cash Provided by (Used in) Financing Activities 0 USD -100%
Net Cash Provided by (Used in) Investing Activities -3.93M USD -148%
Common Stock, Shares, Issued 44.4M shares +0.04%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -10.4M USD -733%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 86M USD -0.04%
Deferred Tax Assets, Valuation Allowance 50.3M USD +11.3%
Deferred Tax Assets, Gross 50.3M USD +11.3%
Operating Lease, Liability 0 USD -100%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -25.3M USD +8.63%
Lessee, Operating Lease, Liability, to be Paid 314K USD -25.2%
Operating Lease, Liability, Current 126K USD +25.1%
Lessee, Operating Lease, Liability, to be Paid, Year Two 136K USD +3%
Lessee, Operating Lease, Liability, to be Paid, Year One 132K USD +24.4%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 33.8K USD -49.1%
Lessee, Operating Lease, Liability, to be Paid, Year Three 46.2K USD -66%
Deferred Tax Assets, Operating Loss Carryforwards 49.8M USD +13.8%
Lessee, Operating Lease, Liability, to be Paid, Year Four 11.7K USD
Additional Paid in Capital 58.1M USD +9.82%
Deferred Tax Assets, Net of Valuation Allowance 0 USD